We feel now is a pretty good time to analyse Nano-X Imaging Ltd.'s (NASDAQ:NNOX) business as it appears the company may be on the cusp of a considerable accomplishment. Nano-X Imaging Ltd.

CTD402 is a universal CAR-T cell product targeting CD7 derived from healthy donors and intended for the treatment of T-ALL/LBL. It is genetically modified to avoid fratricide, graft-versus-host ...